JP7462578B2 - プログラム可能な免疫細胞受容体複合体システム - Google Patents

プログラム可能な免疫細胞受容体複合体システム Download PDF

Info

Publication number
JP7462578B2
JP7462578B2 JP2020573073A JP2020573073A JP7462578B2 JP 7462578 B2 JP7462578 B2 JP 7462578B2 JP 2020573073 A JP2020573073 A JP 2020573073A JP 2020573073 A JP2020573073 A JP 2020573073A JP 7462578 B2 JP7462578 B2 JP 7462578B2
Authority
JP
Japan
Prior art keywords
cells
programmable
receptor
cell
immune cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518428A (ja
JP2021518428A5 (https=
Inventor
キトル、ジョセフ、ディー．
ルワンデ、ジョエル、エス．
タン、ユアンユエン
リアン、シェンウェン
Original Assignee
ファンダメンタル ソリューションズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファンダメンタル ソリューションズ コーポレーション filed Critical ファンダメンタル ソリューションズ コーポレーション
Publication of JP2021518428A publication Critical patent/JP2021518428A/ja
Publication of JP2021518428A5 publication Critical patent/JP2021518428A5/ja
Application granted granted Critical
Publication of JP7462578B2 publication Critical patent/JP7462578B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dermatology (AREA)
JP2020573073A 2018-03-15 2019-03-14 プログラム可能な免疫細胞受容体複合体システム Active JP7462578B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643378P 2018-03-15 2018-03-15
US62/643,378 2018-03-15
US201862651916P 2018-04-03 2018-04-03
US62/651,916 2018-04-03
PCT/US2019/022245 WO2019178342A1 (en) 2018-03-15 2019-03-14 Programmable immunocyte receptor complex system

Publications (3)

Publication Number Publication Date
JP2021518428A JP2021518428A (ja) 2021-08-02
JP2021518428A5 JP2021518428A5 (https=) 2022-03-10
JP7462578B2 true JP7462578B2 (ja) 2024-04-05

Family

ID=67905164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573073A Active JP7462578B2 (ja) 2018-03-15 2019-03-14 プログラム可能な免疫細胞受容体複合体システム

Country Status (6)

Country Link
US (3) US20190284255A1 (https=)
EP (1) EP3765093A4 (https=)
JP (1) JP7462578B2 (https=)
KR (2) KR20250151559A (https=)
CN (1) CN112955184A (https=)
WO (1) WO2019178342A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11117936B2 (en) * 2017-11-10 2021-09-14 University of Pittsburg—Of the Commonwealth System of Higher Education Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
CN112955184A (zh) 2018-03-15 2021-06-11 基本解决方案公司 可编程免疫细胞受体复合物系统
US20220242929A1 (en) * 2019-08-05 2022-08-04 Cartherics Pty. Ltd. Immune cells expressing modified cell receptors and methods of making

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
WO2015095895A1 (en) 2013-12-20 2015-06-25 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
US20160289775A1 (en) 2015-03-31 2016-10-06 Fundamental Solutions Corporation Biosensor system for the rapid detection of analytes
US20170258835A1 (en) 2014-10-31 2017-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874239A (en) 1993-07-30 1999-02-23 Affymax Technologies N.V. Biotinylation of proteins
GB9721075D0 (en) * 1997-10-03 1997-12-03 Cancer Res Campaign Tech Materials and methods relating to the stimulation of cells
FI20021518A0 (fi) * 2002-08-23 2002-08-23 Jyvaeskylaen Yliopisto Avidiinin lämpökestävyyden lisääminen
JP2015524255A (ja) * 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
ES2893879T3 (es) * 2015-03-31 2022-02-10 Fundamental Solutions Corp Sistema biosensor para la detección rápida de analitos
WO2016196384A1 (en) * 2015-05-29 2016-12-08 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
US12121539B2 (en) * 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
CN112955184A (zh) 2018-03-15 2021-06-11 基本解决方案公司 可编程免疫细胞受体复合物系统

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
WO2015095895A1 (en) 2013-12-20 2015-06-25 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
US20170258835A1 (en) 2014-10-31 2017-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
US20160289775A1 (en) 2015-03-31 2016-10-06 Fundamental Solutions Corporation Biosensor system for the rapid detection of analytes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lohmueller JJ, et al.，mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting，Oncoimmunology，7(1)，2017年10月26日，e1368604

Also Published As

Publication number Publication date
KR102867256B1 (ko) 2025-10-01
CN112955184A (zh) 2021-06-11
US12234273B2 (en) 2025-02-25
EP3765093A1 (en) 2021-01-20
EP3765093A4 (en) 2021-12-08
US20200299352A1 (en) 2020-09-24
WO2019178342A1 (en) 2019-09-19
JP2021518428A (ja) 2021-08-02
KR20210018196A (ko) 2021-02-17
KR20250151559A (ko) 2025-10-21
US20190284255A1 (en) 2019-09-19
US20250197472A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
JP7822340B2 (ja) キメラ抗原受容体およびその使用
US20250171540A1 (en) Protein-based t-cell receptor knockdown
JP6783797B2 (ja) 抗がん融合ポリペプチド
JP6041799B2 (ja) Ｔｒａｉｌｒ２特異的多量体足場
ES2945360T3 (es) Sistema de señalización
JP2021072831A (ja) 多様な多重抗原のターゲティングのための汎用的キメラ抗原受容体を発現する免疫細胞および該免疫細胞の製造方法ならびに該免疫細胞の、癌、感染症および自己免疫疾患の治療のための使用
US20250197472A1 (en) Programmable immunocyte receptor complex system
JP2019527041A (ja) Ｔ細胞受容体及びその使用
CN113166226A (zh) 表达显性负性fas的免疫应答细胞及其用途
US20230346938A1 (en) Chimeric antigen receptors targeting cd19 and use thereof
JP2023554674A (ja) 遺伝子改変細胞追跡用ペプチドマーカー
JP2022549994A (ja) Ｓｓｘ２抗原の短いペプチドを識別するｔ細胞受容体
CN114685659B (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
HK40067100A (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240326

R150 Certificate of patent or registration of utility model

Ref document number: 7462578

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150